Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.

BACKGROUND: Traditionally, vaccine development against the blood-stage of Plasmodium falciparum infection has focused on recombinant protein-adjuvant formulations in order to induce high-titer growth-inhibitory antibody responses. However, to date no such vaccine encoding a blood-stage antigen(s) al...

Full description

Bibliographic Details
Main Authors:	Sheehy, S, Duncan, C, Elias, S, Biswas, S, Collins, K, O'Hara, G, Halstead, F, Ewer, K, Mahungu, T, Spencer, A, Miura, K, Poulton, I, Dicks, M, Edwards, N, Berrie, E, Moyle, S, Colloca, S, Cortese, R, Gantlett, K, Long, C, Lawrie, A, Gilbert, S, Doherty, T, Nicosia, A, Hill, A, Draper, S
Format:	Journal article
Language:	English
Published:	Public Library of Science 2012

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.

Similar Items